【摘要】 目的:探讨胶体32P与p53基因治疗肺癌胸腔积液的近期疗效和毒副作用。方法:65例确诊为肺癌并发单侧癌性胸腔积液的患者,随机分为3组。A组用重组人p53腺病毒注射液联合胶体32 P-磷酸铬(胶体32 P)治疗,B组单用胶体32P,C组单用重组人p53腺病毒注射液治疗。各入组者均每月治疗1次,治疗2次后评价疗效。结果:A组总有效率为81.8%,B组总有效率为52.4%,C组总有效率为40.9%,B组与C组之间比较,差异无统计学意义,χ2=0.57,P>0.05;B、C组分别与A组比较,差异均有统计学意义,χ2值分别为4.24和7.77,P值均<0.05;3组患者恶心、呕吐和粒细胞减少差异无统计学意义,A和C组均有5例发热,与B组无发热比较,差异有统计学意义,P值均为0.048。结论:单独使用胶体32P或p53基因治疗肺癌胸腔积液疗效有限;胶体32P与p53基因联合治疗可以有效地控制肺癌胸腔积液。更多还原

【Abstract】 OBJECTIVE: To evaluate the curative effect and side effect of colloidal 32P and p53 gene for the treatment of malignant pleural effusion induced by lung cancer.METHODS: Totally 65 patients diagnosed as lung cancer with single side malignant pleural effusion were randomly divided into 3 groups.The patients of group A were treated by recombinant adenovirus p53 injection(rAD-p53) combined with colloidal chromic phosphate 32P(colloidal 32P).The patients of group B were treated by colloidal 32P.The patients of group C were treated by recombinant rAD-p53,per month.The therapeutic effects were evaluated after 2 courses.RESULTS: The total effective rate(CR+PR) was 81.8% in group A and 52.4% in group B and 40.9% in group C.There was no significant difference between group B and C(χ2=0.57,P>0.05),but there was significant difference between A and 2 other groups(χ2 were 4.24 and 7.77 respectively,P<0.05).CONCLUSION: The effect of individual use of colloidal 32P or rAd-p53 for the treatment of malignant pleural effusion induced by lung cancer is limited,the combination of both can effectively control pleural effusion induced by lung cancer.更多还原